AXON Neuroscience is a clinical-stage biotech company founded in 1999 with a specialized team of researchers focused exclusively on tau immunotherapies and tau diagnostic platforms. AXON has identified and wholly owns several compounds which are being investigated as potentially disease-modifying therapies for the treatment of Alzheimer's disease and other tauopathies. The two lead compounds are the active vaccine AADvac1 and the monoclonal antibody AADvac2. The tau vaccine AADvac1 has potential to be the first breakthrough therapy to address Alzheimer's disease and help millions of people suffering from the devastating disease. Axon is also developing a suite of diagnostic assays to more accurately identify patients with potential tau-derived brain diseases that can benefit from its novel therapeutic candidates.
Company Details
- Employees
- 31
- Founded
- -
- Address
- Dvořákovo Nábrežie 10, Bratislava,811 02,slovakia
- Phone
- 866.658.3979
- of****@****ence.eu
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- axon-neuroscience.eu
- HQ
- Bratislava
Axon Neuroscience Questions
Axon Neuroscience's helpline number is 866.658.3979
Axon Neuroscience's website is axon-neuroscience.eu
Axon Neuroscience's LinkedIn profile is https://sk.linkedin.com/company/axon-neuroscience-se
Axon Neuroscience has
31 employees.
View email and phone details for 31
employees at Axon Neuroscience.
Axon Neuroscience's industry is
Biotechnology Research
Axon Neuroscience's top competitors are
Biogen,
Oligomerix, Inc,
Neurotrope Inc.,
Receptos, A Wholly-Owned Subsidiary Of Celgene,
Mitsubishi Tanabe Pharma Corporation,
Evotec,
Neuralstem, Inc.,
Ulysses Neuroscience Limited,
Ac Immune,
Futureneuro.
Axon Neuroscience's support email address is office@axon-neuroscience.eu
Axon Neuroscience's categories are Biotechnology Research
Axon Neuroscience's founding year is 1999
